(Part three of a four-part series)
See previous parts of the series:
MEAI is a potent synthetic molecule essentially developed in the form of a powder.
Nonetheless, for its Alcohol Use Disorder (AUD) study, developer Clearmind Medicine (NASDAQ: CMND) will create a hard-gel capsule so that the clinical trial participants can self-administer the psychedelic.
For the alcohol substitution product, the company is aiming to make MEAI take the shape of a beverage.
Several doses were tested in the preclinical stage so far. “We started from something relatively low -yet what we found to be effective in the other animal studies that we had already performed- and we went up to three times higher …